rfj. Starting from the baseline that you know far more about NASH then I probably ever will ....a question if U don't mind . The placebo rates in the P2 study of VK2809 ( 2020 ) seem quite high ...% of patients experiencing >30% reduction in Liver fat ....22.2 % in the placebo arm ? Am I understanding that correctly ?
Have you compared their data to ENTB's P2B ENLIVEN trial data . I'd appreciate your analysis if U have time
I have a small position in VKTX . Waited until after their capital raise and then had to chase it higher :--( Similar position in ETNB that I've held for longer
News 
Market Data 
Discover 
